Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients


29 Sep 2019


Poster Display session 2


Tumour Site

Neuroendocrine Neoplasms


Carine Mauro


Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256


C.D.C. Mauro1, V.H.F. de Jesus1, M. Barros1, F.P. Costa2, R.F. Weschenfelder3, N. D’Agustini3, M. Angel4, R. Luca4, J.E. Nuñez5, J.M. O'Connor4, R.P. Riechelmann1

Author affiliations

  • 1 Medical Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 2 Medical Oncology, Hospital Sirio Libanes, 01308050 - Sao Paulo/BR
  • 3 Medical Oncology, Hospital Moinhos de Vento, 90035001 - Porto Alegre/BR
  • 4 Medical Oncology, Instituto Alexander Fleming, C1426ANZ - Buenos Aires/AR
  • 5 Medical Oncology, Instituto do Cancer do Estado de Sao Paulo, 01246000 - Sao Paulo/BR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3581


The incidence of infections is poorly studied in patients (pts) with neuroendocrine (NET) tumors treated with everolimus (eve) outside of clinical trials. We aimed to evaluate the incidence and risk factors for opportunistic infections (OpI) or any serious infection among eligible pts.


Retrospective multicenter Latin American cohort of consecutive pts with advanced NET who received at least one dose of eve. Duration of eve, comorbidities, organ dysfunctions, institution, type of prior treatment and concurrent immunosuppressive condition were tested for possible associations with serious (grade 3-5) infections in univariate and multivariable logistic regression models.


111 pts from 5 centers were included: most were men (57.7%) and had pancreatic NET (49.5%). The median duration of eve treatment was 8.9 months and 30 (27%) pts required a dose reduction of eve due to any toxicity. The median overall survival of pts was 54.3 months. In a median follow-up of 32.9 months, 34 (30.6%) pts experienced infections of any grade, 24 (21.6%, 95% confidence interval [CI]: 12.9 – 28.5%) pts had a serious infection and 8 (7.2%, 95% CI: 2.6 – 12.6%) had at least one OpI. Among pts with OpI, the pathogens were Candida sp, Toxoplasma gondi, Pneumocystis sp and Cryptococcus sp; the most common serious infections were pneumonia and gastrointestinal infection. Eight pts (7.2%) died and all deaths were deemed as related to eve. The multivariable analysis identified eve duration (every 6-month increase; Odds Ratio [OR]: 1.26, 95%CI: 1.02-1.55; p = 0.04) and Charlson comorbidity score (OR: 1.47, 95% CI: 1.03-2.08; p = 0.03) as independent risk factors for serious infection.


Infections are more frequent in NET pts using eve than previously reported by clinical trials - 2% had serious infections in the RADIANT-3 trial. Pts on eve should be closely monitored for infections, especially those receiving eve for several months.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Rachel Riechelmann.


Has not received any funding.


J.M. O’Connor: Honoraria (self): Novartis. R.P. Riechelmann: Honoraria (self): Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.